Inactive Instrument

News Galapagos NV Euronext Bruxelles

Stocks

GLPG

BE0003818359

Biotechnology & Medical Research

End-of-day quote Euronext Bruxelles
-	-

23/09	Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says	MT
23/09	RBC Upgrades Lakefront Biotherapeutics to Outperform From Sector Perform, Adds Speculative Risk, Raises Price Target to $45 From $26	MT

All News

Mentions Relevance

30/09	Acquisition of Own Shares	GL
23/09	Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says	MT
23/09	RBC Upgrades Lakefront Biotherapeutics to Outperform From Sector Perform, Adds Speculative Risk, Raises Price Target to $45 From $26	MT
23/09	Acquisition of Own Shares	GL
16/09	Lakefront Biotherapeutics NV Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 05:35 PM
16/09	Acquisition of Own Shares	GL
09/09	Acquisition of Own Shares	GL
09/09	Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference	GL
02/09	Acquisition of Own Shares	GL
26/08	Acquisition of Own Shares	GL
25/08	U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus	GL
25/08	Lakefront Receives Transparency Notification from Bank of America	GL
19/08	Acquisition of Own Shares	GL
13/08	Acquisition of Own Shares	GL
12/08	Tranche Update on Lakefront Biotherapeutics NV's Equity Buyback Plan announced on June 9, 2026.	CI
11/08	RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating	MT
11/08	Morgan Stanley Adjusts PT on Lakefront Biotherapeutics to $26 From $30, Maintains Equalweight Rating	MT
11/08	Lakefront Biotherapeutics H1 Net Profit From Continuing Operations EUR15.8 Mln	RE
11/08	Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update	GL
11/08	Lakefront Biotherapeutics NV Reports Earnings Results for the Half Year Ended June 30, 2026	CI
05/08	Acquisition of Own Shares	GL
29/07	Acquisition of Own Shares	GL
22/07	Acquisition of Own Shares	GL
15/07	Acquisition of Own Shares	GL
14/07	Lakefront Biotherapeutics NV Announces Resignation of Paulo Fontoura as Director	CI